Toronto, May 3-4, 2006 - Through the two days of the event (http://www.biofinance.ca)  over one hundred (mostly) CEO’s give half-hour presentations on their company's technology, team, progress to date and go-forward plans. Specialty panels by investors at breakfast and lunch framed each day.

BioFinance 2006 is the Canadian Life Science industry's leading investor conference. The meeting brings together key industry players to consider investment opportunities and issues affecting companies in biotechnology, medical devices, diagnostics and research tools. Participants include senior life science executives, institutional and venture capital investors, industry analysts, corporate finance executives and experts from the scientific and medical communities in Canada, the United States, Europe and Asia.

Michael H. May spoke on day two of the conference which took place at the Toronto Mariott.

These blog entries summarize what we heard and experienced, with some interpretation and analysis. Rimon Therapeutics engaged us to "blog the event" as part of their ongoing PR program to promote their company and the Canadian Biotechnology sector. 

Thanks to Michael Stinson, Executive Director, BioFinance 2006 for inviting us to attend the event as "Citizen Journalists".

Click on the BioFinance 2006 on the top left to read more. We welcome your comments.

Howard Oliver for Rimon Therapeutics

www.whatifwhatnext.com